Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1

Autor:	Santo R. Cortina, R. J. Griffiths, Marcie L. Vaughn-Bowser, Arturo Lopez-Anaya, Lori L. Lopresti-Morrow, Kim F. McClure, Kathleen M. Donahue, Shunda M. McGahee, Mary E. Lame, Christopher S. Jones, James D. Eskra, Ralph P. Robinson, Ivan G. Otterness, Jennifer L. Liras, Matthew R. Reese, Lisa M. Tobiassen, Sue A. Yocum, Gary J. Martinelli, Peter G. Mitchell, Lawrence A. Reiter, Marcia L. Bliven
Rok vydání:	2004
Předmět:	Matrix metalloproteinase inhibitor Stereochemistry Clinical Biochemistry Pharmaceutical Science Matrix Metalloproteinase Inhibitors Hydroxamic Acids Biochemistry Chemical synthesis Structure-Activity Relationship chemistry.chemical_compound Matrix Metalloproteinase 13 Drug Discovery Humans Structure–activity relationship Protease Inhibitors Molecular Biology Pyrans chemistry.chemical_classification Sulfonamides Hydroxamic acid integumentary system biology Bicyclic molecule Chemistry Organic Chemistry Matrix Metalloproteinases Sulfonamide Pyran Enzyme inhibitor Hepatocytes biology.protein Molecular Medicine Matrix Metalloproteinase 1
Zdroj:	Bioorganic & Medicinal Chemistry Letters. 14:3389-3395
ISSN:	0960-894X
DOI:	10.1016/j.bmcl.2004.04.083
Popis:	The SAR of a series of sterically hindered sulfonamide hydroxamic acids with relatively large P1' groups is described. The compounds typically spare MMP-1 while being potent inhibitors of MMP-13. The metabolically more stable compounds in the series contain either a monocyclic or bicyclic pyran ring adjacent to the hydroxamate group. Despite the sparing of MMP-1, pre-clinical and clinical studies revealed that fibrosis in rats and MSS in humans is still produced.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf1b568cb8f74bdeb9c13de17634182 https://doi.org/10.1016/j.bmcl.2004.04.083 Zobrazit plný text záznamu Full Text from ScienceDirect